You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業(09939.HK)與GENSUN訂立PD-L1及TGF-ß許可
格隆匯 08-20 23:05

格隆匯 8 月 20日丨開拓藥業(09939.HK)公告,於2020年8月20日,集團的全資附屬公司開拓藥業(廣東)有限公司("被許可人")與於上海證券交易所科創板(科創板)上市的蘇州澤璟生物製藥股份有限公司間接附屬公司Gensun BiopharmaInc.("Gensun")訂立獨家許可協議("許可協議"),據此,集團自Gensun獲得(其中包括)獨家許可,以利用GS19PLB-1C("化合物")("許可產品")進行產品研究、開發、臨牀試驗、註冊、製造及商業化,以及在使用化合物時製造、使用、出售、要約出售、進口及出口許可產品,並以其他方式利用許可權利,以用於預防、防治措施、治療、治癒或改善位於大中華(包括中華人民共和國("中國")、香港、澳門及台灣)的任何人類疾病或醫療狀況。集團有責任盡合理的商業努力以開發及商業利用許可產品。

化合物是由PD-L1拮抗劑抗體及TGF-?胞外域組成的雙標靶抗體,具有同時抑制PD-L1及TGF-ß的高活性。化合物具有治療多種實體瘤的潛力,包括非小肺癌細胞、膽道癌、三陰性乳癌及與HPV相關的腫瘤(如子宮頸癌),且有可能成為同類最佳藥物。透過基因工程修飾,化合物能夠減少中國倉鼠卵巢(CHO)細胞表達蛋白中的降解或片段化,從而使其更易於商業化生產。

據公司所知,公司相信其是中國研究PD-L1/TGF-ß雙靶點抗體第一梯隊的企業。Gensun擁有化合物的全球知識產權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account